Skip to main content
OpenTrials
Completed

NCT Number: NCT04846595

Aspects of Vulnerability of People Living with HIV in the Alpine Arc Region

HIV infection in France has become a chronic disease and treatment has allowed patients to increase their life expectancy. However, these promising results suffer from a very large variability within the socio-epidemiological subgroups, and life expectancy at 20 years of age is still one third lower than in the general population. Few studies of metropolitan cohorts investigated precariousness as an independent risk factor for mortality. The investigators chose to consider the vulnerability of people living with HIV (PLWHA) through the measurement of a validated French quantitative score, called EPICES ("Évaluation de la précarité et des inégalités de santé dans les centres d'examens de santé ", Evaluation of precariousness and health inequalities in health examination centers).

Completed

Looking for future studies?

Notify Me

Key information

About this study

HIV infection in France has become a chronic disease and treatment has allowed patients to increase their life expectancy. However, these promising results suffer from a very large variability within the socio-epidemiological subgroups, and life expectancy at 20 years of age is still one third lower than in the general population. Few studies of metropolitan cohorts investigated precariousness as an independent risk factor for mortality. The investigators chose to consider the vulnerability of people living with HIV (PLWHA) through the measurement of a validated French quantitative score, called EPICES (Evaluation of precariousness and health inequalities in health examination centers). Using a self-administered questionnaire administered during an annual follow-up visit to an infectious disease specialist, the investigators seek to define in the alpine arc region in france, socio-demographic data associated with greater precariousness among PLWHA.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Any person living with HIV presenting for consultation with their infectious disease referrer.
  • Patient followed for at least 6 months for their HIV infection
  • Patient with undetectable or detectable HIV viral load
  • Patient of legal age at the time of the study
  • Patient informed of the study and having expressed no objection to the collection of health data

Exclusion criteria

  • Patient opposed or unable to express opposition to participation in the study
  • Patient is a minor at the time of the study
  • Patient taking antiretroviral therapy for less than 6 months

Treatment and study plan

Self questionnaire

Other

Evaluate the demographic variables and medical characteristics of people living with HIV in the Alpine Arc region

Primary outcomes

  1. Variables of vulnerability

    Time frame: one day

    Evaluation of the variables associated with a state of vulnerability according to the "EPICES" scale (at a threshold of 30.17/100), among the social, demographic and medical characteristics of people living with HIV in the Alpine Arc region characteristics of people living with HIV in the Alpine Arc region

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Annecy Genevois

Other

Registry information

Acronym: ASPEGIC

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Apr 15, 2021
Registry last updated
Feb 13, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.